InventisBio (688382)2024-10-29 08:47Financial Performance - The company's operating revenue for Q3 2024 was ¥4,283,084.62, a decrease of 90.92% compared to the same period last year[2]. - The net profit attributable to shareholders for Q3 2024 was -¥91,088,164.68, with a year-to-date net profit of -¥305,306,509.72[2]. - Total operating revenue for the first three quarters of 2024 was ¥19,156,299.24, a significant decrease from ¥127,169,811.32 in the same period of 2023, representing a decline of approximately 84.9%[15]. - Net profit for the first three quarters of 2024 was -¥305,306,509.72, compared to -¥241,261,887.25 in 2023, indicating a worsening loss of approximately 26.6%[16]. - The basic and diluted earnings per share for the first three quarters of 2024 were both -¥0.53, compared to -¥0.42 in 2023, indicating a decline in earnings performance[17]. - Other comprehensive income after tax attributable to shareholders was -¥1,629,834.88 in 2024, compared to -¥592,304.62 in 2023, indicating a worsening of approximately 174.5%[16]. Research and Development - Research and development expenses totaled ¥86,765,416.51 in Q3 2024, a decrease of 22.39% year-over-year, representing 2,025.77% of operating revenue[4]. - The proportion of R&D expenses to operating revenue increased by 1,788.75 percentage points in Q3 2024 compared to the previous year[7]. - Research and development expenses were ¥295,676,116.12 in 2024, down from ¥349,006,011.76 in 2023, a decrease of about 15.3%[16]. - The company has ongoing investments in new technologies and product development, although specific figures were not disclosed in the report[11]. Assets and Liabilities - Total assets at the end of Q3 2024 were ¥1,891,407,290.62, down 12.53% from the end of the previous year[4]. - The company's current assets totaled RMB 1,831,610,771.86, down 13.8% from RMB 2,123,120,943.27 at the end of 2023[12]. - The company's total liabilities were RMB 156,430,452.54, a slight decrease of 5% from RMB 164,669,523.57[13]. - The company's total equity attributable to shareholders decreased to ¥1,734,976,838.08 from ¥1,997,602,519.77, a decline of approximately 13.1%[14]. - The total liabilities and equity decreased from ¥2,162,272,043.34 to ¥1,891,407,290.62, reflecting a reduction of about 12.5%[14]. Cash Flow - The net cash flow from operating activities was -289,602,708.75, compared to -234,600,234.01 in the previous period, indicating a decline in operational cash flow[19]. - Total cash inflow from operating activities amounted to 32,905,278.31, while cash outflow was 322,507,987.06, resulting in a significant cash outflow[19]. - The cash flow from investment activities was -181,557,575.16, a decrease from a positive cash flow of 1,919,032.28 in the previous period[19]. - Cash and cash equivalents at the end of the period were 739,523,993.87, down from 1,995,728,106.17 at the end of the previous period[20]. - The net cash flow from financing activities was -2,466,864.08, compared to -9,658,953.38 in the previous period, showing an improvement in financing cash flow[20]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,542[8]. - InventisBio Hong Kong Limited held 19.13% of the shares, totaling 110,329,937 shares[8]. - There were no significant changes in the shareholding structure among the top shareholders during the reporting period[11]. Government Subsidies and Tax - The company recognized government subsidies of ¥6,900,000.00 during the reporting period[5]. - The company received tax refunds amounting to 27,584,642.95 during the reporting period[19]. Market and Operational Strategy - The company experienced a significant decline in revenue primarily due to a high base from last year's technology licensing and cooperation income[7]. - The company is exploring market expansion opportunities, particularly in the Asia-Pacific region, to enhance its competitive position[11]. Accounting Standards - The company did not apply new accounting standards for the current reporting period[21].